A study to determine humoral and T-cell mediated immune responses to SARS-CoV-2 vaccination in persons with chronic liver disease and immunosuppressed solid organ transplant recipients
Latest Information Update: 28 Dec 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 28 Dec 2022 New trial record
- 08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases